{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/699d8cb1dc0d51c3f177446a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How Xellia Is Reshaping Europe’s Antibiotics Market | CEO Michael Kocher","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1771932035490-9279f65b-f2dd-4bdc-946c-3795cff79b2a.jpeg?height=200","description":"<p>What does it take to turn around a global antibiotic manufacturer and redefine its future in one of the toughest market environments in Europe?</p><p><br></p><p>This week, in another episode of the Making It in Manufacturing Spotlight Series, hosted by @Thomas McMann we sit down with @Michael Kocher, CEO of @Xellia, who brings over two decades of leadership experience across global pharma and large-scale operations. With a career spanning senior roles in big-pharma and now leading a globally influential API manufacturer, Michael shares a remarkably honest look at the realities, decisions, and opportunities shaping Xellia today.</p><p> </p><p>In this episode, Michael covers:</p><p><br></p><p>- Surprises from his first two years as CEO, including the talent, mindset, and culture he found inside Xellia.</p><p>- His early strategic focuses, stabilising finances, divesting business operations, and rebuilding a sustainable foundation.</p><p>- Xellia’s key differentiators, its portfolio of anti-infectives, their role in fighting severe infections and AMR.</p><p>- The decision to close its Copenhagen manufacturing site over 8-10 years, why the long-term shift was necessary and how it impacts future manufacturing.</p><p>- European policy and market pressures, reimbursement challenges, OPEX subsidies, and why reshoring isn’t realistic.</p><p>- Future priorities, financial strengthening, product transfers, market-share growth, and new product launches.</p><p>- Biggest opportunities ahead, expanding the fermentation-based API portfolio and doubling down on critical medicines. Full Podcast</p><p> </p><p>Be sure to check out this episode to hear Michael’s candid perspective on leadership, manufacturing, European policy, and what it truly takes to win in today’s API landscape.</p><p><br></p><p>Follow ARTO:</p><p>LinkedIn: https://www.linkedin.com/company/artotalent</p><p>Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng</p><p>Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&amp;utm_source=qr</p><p>TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&amp;_r=1</p><p>Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575</p><p>Website: https://arto-talent.com/</p><p>YouTube: https://www.youtube.com/@life_sciences</p><p><br></p><p>Michael Kocher</p><p>CEO at Xellia Pharmaceuticals</p><p>LinkedIn: https://www.linkedin.com/in/michael-kocher-191863a/</p><p><br></p><p>Thomas McMann</p><p>Director - Contracts Division</p><p>LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/</p>","author_name":"ARTO Talent"}